Literature DB >> 30675438

Global overview of health systems oversight and financing for kidney care.

Aminu K Bello1, Mona Alrukhaimi2, Gloria E Ashuntantang3, Ezequiel Bellorin-Font4, Mohammed Benghanem Gharbi5, Branko Braam1, John Feehally6, David C Harris7, Vivekanand Jha8,9, Kailash Jindal1, David W Johnson10,11,12, Kamyar Kalantar-Zadeh13, Rumeyza Kazancioglu14, Peter G Kerr15,16, Meaghan Lunney17, Timothy Olusegun Olanrewaju18, Mohamed A Osman1, Jeffrey Perl19,20, Harun Ur Rashid21, Ahmed Rateb1, Eric Rondeau22,23, Aminu Muhammad Sakajiki24, Arian Samimi1, Laura Sola25, Irma Tchokhonelidze26, Natasha Wiebe1, Chih-Wei Yang27, Feng Ye1, Alexander Zemchenkov28,29, Ming-Hui Zhao30,31,32,33, Adeera Levin34.   

Abstract

Reliable governance and health financing are critical to the abilities of health systems in different countries to sustainably meet the health needs of their peoples, including those with kidney disease. A comprehensive understanding of existing systems and infrastructure is therefore necessary to globally identify gaps in kidney care and prioritize areas for improvement. This multinational, cross-sectional survey, conducted by the ISN as part of the Global Kidney Health Atlas, examined the oversight, financing, and perceived quality of infrastructure for kidney care across the world. Overall, 125 countries, comprising 93% of the world's population, responded to the entire survey, with 122 countries responding to questions pertaining to this domain. National oversight of kidney care was most common in high-income countries while individual hospital oversight was most common in low-income countries. Parts of Africa and the Middle East appeared to have no organized oversight system. The proportion of countries in which health care system coverage for people with kidney disease was publicly funded and free varied for AKI (56%), nondialysis chronic kidney disease (40%), dialysis (63%), and kidney transplantation (57%), but was much less common in lower income countries, particularly Africa and Southeast Asia, which relied more heavily on private funding with out-of-pocket expenses for patients. Early detection and management of kidney disease were least likely to be covered by funding models. The perceived quality of health infrastructure supporting AKI and chronic kidney disease care was rated poor to extremely poor in none of the high-income countries but was rated poor to extremely poor in over 40% of low-income countries, particularly Africa. This study demonstrated significant gaps in oversight, funding, and infrastructure supporting health services caring for patients with kidney disease, especially in low- and middle-income countries.

Entities:  

Keywords:  delivery of health care; developing countries; global health care; global health governance; health care financing; nephrology

Year:  2018        PMID: 30675438      PMCID: PMC6336220          DOI: 10.1016/j.kisu.2017.10.008

Source DB:  PubMed          Journal:  Kidney Int Suppl (2011)        ISSN: 2157-1716


  9 in total

1.  The influence of the National Health Insurance scheme of the Lao People's Democratic Republic on healthcare access and catastrophic health expenditures for patients with chronic renal disease, and the possibility of integrating organ transplantation into the health financing system.

Authors:  Somdeth Bodhisane; Sathirakorn Pongpanich
Journal:  Health Res Policy Syst       Date:  2022-06-20

Review 2.  The role of kidney transplantation as a component of integrated care for chronic kidney disease.

Authors:  Philip J O'Connell; Mark Brown; Tak Mao Chan; Rolando Claure-Del Granado; Simon J Davies; Somchai Eiam-Ong; Mohamed H Hassan; Kamyar Kalantar-Zadeh; Adeera Levin; Dominique E Martin; Elmi Muller; Shahrzad Ossareh; Irma Tchokhonelidze; Michele Trask; Ahmed Twahir; Anthony J O Were; Chih-Wei Yang; Alexander Zemchenkov; Paul N Harden
Journal:  Kidney Int Suppl (2011)       Date:  2020-02-19

3.  A systematic review and meta-analysis of acute kidney injury in the intensive care units of developed and developing countries.

Authors:  Fernando de Assis Ferreira Melo; Etienne Macedo; Ana Caroline Fonseca Bezerra; Walédya Araújo Lopes de Melo; Ravindra L Mehta; Emmanuel de Almeida Burdmann; Dirce Maria Trevisan Zanetta
Journal:  PLoS One       Date:  2020-01-17       Impact factor: 3.240

4.  Assessing the impact of screening, early identification and intervention programmes for chronic kidney disease: protocol for a scoping review.

Authors:  Ikechi G Okpechi; Fergus J Caskey; Abduzhappar Gaipov; Elliot K Tannor; Laura N Hamonic; Gloria Ashuntantang; Jo-Ann Donner; Ana Figueiredo; Reiko Inagi; Magdalena Madero; Charu Malik; Monica Moorthy; Roberto Pecoits-Filho; Vladimir Tesar; Adeera Levin; Vivekanand Jha
Journal:  BMJ Open       Date:  2021-12-16       Impact factor: 2.692

5.  Jian-Pi-Yi-Shen formula enhances perindopril inhibition of chronic kidney disease progression by activation of SIRT3, modulation of mitochondrial dynamics, and antioxidant effects.

Authors:  Xinhui Liu; Ruyu Deng; Xian Wei; Yuzhi Wang; Jiali Weng; Yunlan Lao; Jiandong Lu; Guoliang Xiong; Shunmin Li
Journal:  Biosci Rep       Date:  2021-10-29       Impact factor: 3.840

6.  Prevalence, recognition and management of chronic kidney disease in Japan: population-based estimate using a healthcare database with routine health checkup data.

Authors:  Masato Takeuchi; Kanna Shinkawa; Motoko Yanagita; Koji Kawakami
Journal:  Clin Kidney J       Date:  2021-01-24

7.  Health-Related Quality of Life in Home Dialysis Patients Compared to In-Center Hemodialysis Patients: A Systematic Review and Meta-analysis.

Authors:  Anna A Bonenkamp; Anita van Eck van der Sluijs; Tiny Hoekstra; Marianne C Verhaar; Frans J van Ittersum; Alferso C Abrahams; Brigit C van Jaarsveld
Journal:  Kidney Med       Date:  2020-02-11

8.  Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey.

Authors:  Emily Yeung; A K Bello; Adeera Levin; Meaghan Lunney; Mohamed A Osman; Feng Ye; Gloria Ashuntantang; Ezequiel Bellorin-Font; Mohammed Benghanem Gharbi; Sara Davison; Mohammad Ghnaimat; Paul Harden; Vivekanand Jha; Kamyar Kalantar-Zadeh; Peter Kerr; Scott Klarenbach; Csaba Kovesdy; Valerie Luyckx; Brendon Neuen; Donal O'Donoghue; Shahrzad Ossareh; Jeffrey Perl; Harun Ur Rashid; Eric Rondeau; Emily See; Syed Saad; Laura Sola; Irma Tchokhonelidze; Vladimir Tesar; Kriang Tungsanga; Rumeyza Turan Kazancioglu; Angela Yee-Moon Wang; Natasha Wiebe; Chih-Wei Yang; Alexander Zemchenkov; Minhui Zhao; Kitty J Jager; Fergus Caskey; Vlado Perkovic; Kailash Jindal; Ikechi G Okpechi; Marcello Tonelli; John Feehally; David Ch Harris; David Johnson
Journal:  BMJ Open       Date:  2021-07-09       Impact factor: 2.692

Review 9.  Comorbidities and the COVID-19 pandemic dynamics in Africa.

Authors:  A A Anjorin; A I Abioye; O E Asowata; A Soipe; M I Kazeem; I O Adesanya; M A Raji; M Adesanya; F A Oke; F J Lawal; B A Kasali; M O Omotayo
Journal:  Trop Med Int Health       Date:  2020-10-23       Impact factor: 3.918

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.